EyePoint (EYPT) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed EyePoint (EYPT) over the past year, gaining 101.8% versus a loss of 75.1%. Over five years, NAUT leads with a -68.1% price change compared with -69.8% for EYPT. EyePoint is the larger company by market cap ($290.1 million vs $231.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | NAUT |
|---|---|---|
| Share price | $3.46 | $1.82 |
| Market cap | $290.09M | $231.60M |
| 1-day change | +4.22% | -7.14% |
| YTD return | -81.06% | -6.67% |
| 1-year return | -75.07% | +101.77% |
| 5-year return | -69.76% | -68.13% |
| EPS (TTM) | $-3.90 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $4.31 |
| 52-week low | $3.05 | $0.82 |
| Distance from 52-week high | -81.89% | -57.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +648.84% | +110.44% |
| Average volume | 3.96M | 2.66M |
| Shares outstanding | 83.84M | 127.26M |
| Employees | 214 | 127 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed EYPT by 176.8 percentage points over the past year.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
EYPT vs NAUT FAQ
Which is bigger, EyePoint or Nautilus Biotechnology?
EyePoint (EYPT) is larger, with a market capitalization of $290.09M compared with $231.60M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, EYPT or NAUT?
NAUT returned +101.77% over the past 12 months, compared with -75.07% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Nautilus Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.